American Medical AssociationEffect of Celecoxib vs. Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer

Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. […]

American Society of Clinical OncologyDuration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.